PFE News 28.08 08/13/2014 05:30:49 Pfizer Inc (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 28.08 $PFE

Most active New York Stock Exchange-traded stocks
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:

Final Glance: Pharmaceuticals companies
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Business Highlights
By The Associated Press - AP - Tue Aug 12, 5:05PM CDT
___

UBS AG Contemplates $4.5B Bond Offerings in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:05PM CDT
As per Bloomberg, the Swiss major UBS AG (UBS) is planning corporate bond offerings in the U.S. The bank will be issuing $4.5 billion worth of bonds.

Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica(R) Studies Conducted in China
Business Wire - Tue Aug 12, 4:02PM CDT
Pfizer Inc. (NYSE FE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica(R) (pregabalin) in patients with postherpetic neuralgia (pain after shingles or PHN) and painful diabetic peripheral neuropathy (pDPN), respectively. The PHN Phase 4 study, A0081276, met its primary endpoint by demonstrating a statistically significant reduction in pain when compared to placebo. Separately, the pDPN Phase 3 study, A0081265, did not meet its primary endpoint, a statistically significant change in endpoint mean pain score relative to placebo.

Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PR Newswire Europe - Tue Aug 12, 12:50PM CDT
DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] report to their offering.

Midday Glance: Pharmaceuticals companies
AP - Tue Aug 12, 12:48PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

5 Things Pfizer Inc.'s Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 12, 12:27PM CDT
Big pharma giant Pfizer reported its second quarter earnings results two weeks ago, reminding shareholders that the patent cliff is very real, and that its operations are going through a sizable shift. For the quarter, Pfizer reported that...

Early Glance: Pharmaceuticals companies
AP - Tue Aug 12, 11:14AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Pfizer, 23andMe team up to study bowel disease
By MATTHEW PERRONE - AP - Tue Aug 12, 10:24AM CDT
WASHINGTON (AP) — Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Study Links Viagra(R) to Skin Cancer
Marketwire - Tue Aug 12, 10:20AM CDT
A recent study published in The Journal of the American Medical Association found that men who take Viagra® have an almost 84 percent greater risk of developing melanoma, one of the most aggressive forms of skin cancer. The study analyzed data from more than 25,000 men and controlled for factors such as sun exposure and family medical history.

Entia Biosciences' Supplements Could Prevent Dementia
ACCESSWIRE - Tue Aug 12, 8:55AM CDT
WHITEFISH, MT / ACCESSWIRE / August 12, 2014 / Vitamin D deficiency has been associated with a number of conditions, ranging from cardiovascular disease to certain types of cancers, according to WebMD. On the other side of the coin, research suggests that vitamin D could play a role in the prevention and treatment of diabetes, hypertension, glucose intolerance, multiple sclerosis, and a number of other serious medical conditions.

Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:

23andMe Announces Agreement with Pfizer Inc. to Research Genetics of Ulcerative Colitis and Crohn's Disease
PR Newswire - Tue Aug 12, 8:00AM CDT
23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.

Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular

Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...


AIDS activist takes up a new fight: defending FDA
By MATTHEW PERRONE - AP - Mon Aug 11, 3:49PM CDT
WASHINGTON (AP) — As an AIDS activist in the early 1990s, Gregg Gonsalves traveled to Washington to challenge the Food and Drug Administration.

Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
PR Newswire - Mon Aug 11, 6:00AM CDT
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF® (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 72

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading
Leatt Sets Its Virtual 2026 Shareholder Meeting Date

Updated Category News Views 73

A calendar notice is not a catalyst, but ignoring the calendar is how shareholders miss the small moments that matter. Leatt Corporation has scheduled its 2026 virtual annual general meeting of stockholders for Friday, November 20, at 11:00 AM Eastern Time. For holders of OTCQB:LEAT, this is a basic corporate-governance event, not a new product launch or a financial...

Continue Reading
Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 98

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
Devicie Broadens Browser Security Across Device Fleets

Updated Category News Views 57

Browsers have quietly become the front door, side door, and occasionally the busted basement window of corporate security. Devicie’s newly expanded Edge for Business Reporting Connector tackles that uncomfortable reality by pulling browser security events from Windows, macOS, iOS, and Android into the same console customers use to oversee Microsoft Intune environments....

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 92

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 77

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 109

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 48

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 96

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 87

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading

Top 5 Most Recently Viewed Articles

How the Bank of England's Interest Rate Decision Impacts Your Investments

Updated Category Economy Views 316

Introduction The Bank of England's decision on interest rates plays a critical role in shaping the economic landscape, with far-reaching effects on your investment portfolio. Changes in these rates can influence stock market performance, affect bond yields, and alter the attractiveness of various asset classes. Understanding how these adjustments can impact your...

Continue Reading
Eric Beightel Joins Environmental Science Associates Team

Updated Category News Views 131

Eric Beightel Appointed as Federal Strategy Director Environmental Science Associates (ESA) is thrilled to welcome Eric Beightel to its team as the new Federal Strategy Director. With a comprehensive background in environmental policy, Beightel brings a wealth of knowledge to ESA, poised to enhance its capabilities in navigating the complexities of federal regulations....

Continue Reading
iBio Inc. Showcases Innovative Antibody Developments Soon

Updated Category News Views 257

Exciting Presentations from iBio Inc. iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his...

Continue Reading
Turkey's Markets Experience A Dip as Investors React

Updated Category News Views 319

A Dip in Turkey's Stock Market Performance Turkey's stock market witnessed a decline recently, with shares closing lower on the exchange. The BIST 100 index, a benchmark for investors, finished down by 0.60%, indicating a challenging trading day for stakeholders. Sectors Impacting Market Trends Leading the Declines A noticeable drop in market values was driven by several...

Continue Reading
Medline Celebrated for Innovation in Respiratory Care Solutions

Updated Category News Views 180

Medline secured the prestigious Zenith Award from the American Association for Respiratory Care (AARC) in 2024, marking a significant moment for traders and healthcare pros alike. This award wasn’t just handed out; it was earned by only eight companies out of over 300 nominees. The kind of spotlight that draws attention can shake up market sentiments. Why Medline Stood...

Continue Reading